Boehringer Ingelheim licenses six oncology programs; Nxera out-licenses EP4 agonist to AbbVie
The pharma licensing roundup covered Boehringer's deal with Sino Biopharmaceutical and Nxera's EP4 agonist agreement with AbbVie.
Read at Pharmaceutical Executive →